

# Nigel S B Rawson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/882040/publications.pdf>

Version: 2024-02-01

55  
papers

1,063  
citations

623734

14  
h-index

434195

31  
g-index

60  
all docs

60  
docs citations

60  
times ranked

955  
citing authors

#	ARTICLE	IF	CITATIONS
1	Letter and category fluency in community-dwelling canadian seniors: A comparison of normal participants to those with dementia of the Alzheimer or vascular type. <i>Journal of Clinical and Experimental Neuropsychology</i> , 1997, 19, 52-62.	1.3	177
2	Differences in relapse precipitants and coping behaviour between alcohol relapsers and survivors. <i>Behaviour Research and Therapy</i> , 1979, 17, 89-94.	3.1	140
3	Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. <i>Statistics in Medicine</i> , 1995, 14, 2627-2643.	1.6	121
4	Towards a typology of relapse: A preliminary report. <i>Drug and Alcohol Dependence</i> , 1977, 2, 157-162.	3.2	74
5	Assessing the validity of diagnostic information in administrative health care utilization data: experience in Saskatchewan. , 1998, 7, 389-398.		46
6	Hospitalizations for Aplastic Anemia and Agranulocytosis in Saskatchewan. <i>Journal of Clinical Epidemiology</i> , 1998, 51, 1343-1355.	5.0	46
7	Manitoba and Saskatchewan administrative health care utilization databases are used differently to answer epidemiologic research questions. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 192-197.e12.	5.0	43
8	Prescription-event monitoring: Methodology and recent progress. <i>Journal of Clinical Epidemiology</i> , 1990, 43, 509-522.	5.0	42
9	Reliability of the recording of hysterectomy in the Saskatchewan health care system. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1996, 103, 891-897.	2.3	32
10	Canadian and US Drug Approval Times and Safety Considerations. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1403-1408.	1.9	26
11	“Cost-effectiveness” Estimates Result in Flawed Decisionmaking in Listing Drugs for Reimbursement. <i>Canadian Journal of Public Health</i> , 2002, 93, 421-425.	2.3	22
12	Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 59.	2.7	21
13	Prescription-Event Monitoring of 10 895 Patients Treated with Alprazolam. <i>British Journal of Psychiatry</i> , 1991, 158, 387-392.	2.8	18
14	Concordance on the Recording of Cancer in the Saskatchewan Cancer Agency Registry, Hospital Charts and Death Registrations. <i>Canadian Journal of Public Health</i> , 2000, 91, 390-393.	2.3	17
15	Timeliness of review and approval of new drugs in Canada from 1999 through 2001: Is progress being made?. <i>Clinical Therapeutics</i> , 2003, 25, 1230-1247.	2.5	16
16	Factors Associated with Celecoxib and Rofecoxib Utilization. <i>Annals of Pharmacotherapy</i> , 2005, 39, 597-602.	1.9	13
17	Canadian, European and United States new drug approval times now relatively similar. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 96, 121-126.	2.7	13
18	The aging male population and medical care for benign prostatic hyperplasia in Canada. <i>Canadian Urological Association Journal</i> , 2010, 4, 123-127.	0.6	13

#	ARTICLE	IF	CITATIONS
19	An Acute Adverse Drug Reaction Alerting Scheme Using the Saskatchewan Health Datafiles. Drug Investigation, 1993, 6, 245-256.	0.6	12
20	Drug safety: withdrawn medications are only part of the picture. BMC Medicine, 2016, 14, 28.	5.5	12
21	Drug Review in Canada: A Comparison With Australia, Sweden, the United Kingdom, and the United States. Drug Information Journal, 1998, 32, 1133-1141.	0.5	10
22	Developing algorithms for healthcare insurers to systematically monitor surgical site infection rates. BMC Medical Research Methodology, 2007, 7, 20.	3.1	10
23	Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: a personal viewpoint. Pharmacoepidemiology and Drug Safety, 2002, 11, 335-340.	1.9	9
24	Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. Pharmacoepidemiology and Drug Safety, 2006, 15, 11-18.	1.9	9
25	Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoconomics research in Canada: anti-viral drugs as an example. Pharmacoepidemiology and Drug Safety, 2009, 18, 1072-1079.	1.9	9
26	National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on "Universal Pharmacare in Canada: A Prescription for Equity in Healthcare". International Journal of Health Policy and Management, 2020, 9, 524-527.	0.9	9
27	Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010. BMC Research Notes, 2013, 6, 82.	1.4	8
28	New drug approval times and safety warnings in the United States and Canada, 1992-2011. Journal of Population Therapeutics and Clinical Pharmacology, 2013, 20, e67-81.	1.4	8
29	The aging Canadian population and hospitalizations for acute myocardial infarction: projection to 2020. BMC Cardiovascular Disorders, 2012, 12, 25.	1.7	7
30	Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 721-730.	1.9	7
31	A developmental test based on the STYCAR sequences used in the National Childhood Encephalopathy Study. Child: Care, Health and Development, 1985, 11, 309-323.	1.7	6
32	Healthcare Databases for Drug Safety Research: Data Validity Assessment Remains Crucial. Drug Safety, 2018, 41, 829-833.	3.2	6
33	Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand. Regulatory Toxicology and Pharmacology, 2019, 101, 24-28.	2.7	6
34	Impact of Preexisting Health Conditions on the Outcome of an Adverse Drug Reaction Alerting Program: Gastrointestinal Disorders Before Piroxicam and Sulindac Therapy. Annals of Pharmacotherapy, 1995, 29, 676-680.	1.9	5
35	Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand. Canadian Journal of Cardiology, 2007, 23, 711-718.	1.7	5
36	25 years of pharmacoepidemiologic innovation: the Saskatchewan health administrative databases. Journal of Population Therapeutics and Clinical Pharmacology, 2011, 18, e245-9.	1.4	5

#	ARTICLE	IF	CITATIONS
37	Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?. Orphanet Journal of Rare Diseases, 2022, 17, .	2.7	5
38	The Timeliness of New Drug Approvals in Canada. International Journal of Health Services, 1995, 25, 153-165.	2.5	3
39	Importation of drugs into the United States from Canada. Cmaj, 2017, 189, E817-E818.	2.0	3
40	What does the new ontario pharmacare plan offer children and young adults with rare disorders?. Journal of Population Therapeutics and Clinical Pharmacology, 2017, 24, 90-98.	1.9	3
41	Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?. Journal of Population Therapeutics and Clinical Pharmacology, 2020, 27, e48-e64.	1.9	3
42	Distribution of Drug-Related Problems Among London Casualty Departments. British Journal of Psychiatry, 1978, 132, 467-472.	2.8	2
43	Ethical issues in pharmacoepidemiologic research using Saskatchewan administrative health care utilization dataDisclaimer: Although this work includes data provided by Saskatchewan Health, the interpretation and conclusions are those of the author and do not necessarily represent those of Saskatchewan Health or the Government of Saskatchewan.. Pharmacoepidemiology and Drug Safety, 2001, 10, 607.	1.9	2
44	Assessing prescription medications for priority regulatory review. Regulatory Toxicology and Pharmacology, 2005, 42, 70-76.	2.7	2
45	Health Canada's use of priority review status for drugs forÂunmetÂneeds. Regulatory Toxicology and Pharmacology, 2015, 73, 391-395.	2.7	2
46	New use of antiarrhythmia drugs in Saskatchewan. Canadian Journal of Cardiology, 2002, 18, 43-50.	1.7	2
47	Need for an improved submission process for listing drugs for reimbursement in Canadian provinces. Canadian Journal of Clinical Pharmacology, 2003, 10, 207-10.	1.1	2
48	Letter to ISPE commentary editor. Pharmacoepidemiology and Drug Safety, 2003, 12, 71-72.	1.9	1
49	Epidemiology in the pharmaceutical Industry: a Canadian perspective. Pharmacoepidemiology and Drug Safety, 2006, 15, 758-762.	1.9	1
50	PUBLIC REIMBURSEMENT OF PRESCRIPTION DRUG USED FOR OFF-LABEL INDICATIONS IN ONTARIO. Canadian Journal of Clinical Pharmacology, 2018, 25, e23-e30.	1.1	1
51	Leading Causes of Mortality and Prescription Drug Coverage in Canada and New Zealand. Frontiers in Public Health, 2020, 8, 544835.	2.7	1
52	UnitedHealth Group. , 0, , 271-280.		1
53	Respiratory Infection and Otitis Media Visits in Relation to Pneumococcal Conjugate Vaccine Use in Saskatchewan. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 179-184.	1.9	0
54	Promoting adherence to medicines: possible lessons for Canada?. Israel Journal of Health Policy Research, 2017, 6, 63.	2.6	0

#	ARTICLE	IF	CITATIONS
55	Prioritisation for therapies based on a disorder's severity: ethics and practicality. Journal of Medical Ethics, 2022, 48, 95-96.	1.8	0